Business Context and Reporting Period
This Form 8-K reports on the 2024 Annual Meeting of Stockholders held by IDEAYA Biosciences, Inc. on May 31, 2024. The Company is an emerging growth company incorporated in Delaware, with its principal executive offices in South San Francisco, California. The report details the voting results for four proposals presented to stockholders of record as of April 4, 2024, when 74,764,628 shares of common stock were outstanding.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and stockholder voting outcomes rather than financial performance.
Material Changes Versus Prior Period
No material financial changes or comparisons to prior periods are disclosed in this filing. The document serves as a current report of the Annual Meeting results.
Guidance, Outlook, and Voting Results
The filing details the outcomes of four stockholder proposals:
- Proposal 1 (Election of Directors): Two Class II directors were elected to serve until the 2027 annual meeting.
- Terry J. Rosen, Ph.D.: 54,533,987 votes for; 14,635,187 votes withheld.
- Wendy L. Yarno: 64,201,258 votes for; 4,521,762 votes withheld.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the year ending December 31, 2024.
- Results: 70,923,175 votes for; 6,295 votes against; 9,414 abstentions.
- Proposal 3 (Say-on-Pay): A non-binding advisory vote to approve executive compensation.
- Results: 62,946,692 votes for; 4,602,338 votes against; 1,646,579 abstentions.
- Proposal 4 (Frequency of Say-on-Pay): A non-binding advisory vote on the frequency of future compensation votes.
- Results: The majority voted for a 1-year frequency (66,248,948 votes), with 3,726 votes for 2 years and 1,282,562 votes for 3 years.
Important Facts for Investors to Verify
- Confirm the specific terms of the newly elected directors' tenure and any related compensation agreements.
- Review the definitive proxy statement (Schedule 14A) filed on April 19, 2024, for detailed background on the proposals and executive compensation.
- Verify the Company's financial status and cash runway in subsequent filings (e.g., 10-Q or 10-K), as this 8-K contains no financial data.
- Note the significant number of votes withheld for Director Terry J. Rosen compared to Wendy L. Yarno, which may indicate stockholder sentiment regarding board composition.